Form 10-Q · Quarterly report
Gilead Sciences 10-Q, filed Oct 30, 2026
- Filed
- CIK
- 0000882095
- Accession no.
- 0000882095-26-000039
Summary
Gilead Sciences reported third-quarter 2026 total revenues of $8.3 billion, up 7% from a year earlier, as HIV product sales rose 18% to $6.2 billion on higher demand and realized prices, including growth in Biktarvy, Descovy and Yeztugo. The quarter also showed a 69% decline in Veklury sales to $86 million on lower COVID-19 hospitalization rates, a 42% increase in Trodelvy sales, and nine-month acquired in-process R&D expenses of $11.3 billion including a $1.75 billion impairment.
Key points
- Total Q3 2026 revenues were $8.3 billion, up 7% year over year, with total product sales up 13% to $8.29 billion.
- HIV product sales rose 18% to $6.2 billion, driven by higher demand and average realized price, including Biktarvy up 10% and Descovy up 49%.
- Veklury sales fell 69% to $86 million in the quarter, which Gilead attributed to lower rates of COVID-19-related hospitalizations; Trodelvy sales rose 42% to $506 million.
- Nine-month acquired in-process R&D expenses were $11.3 billion and included a $1.75 billion impairment, with $229 million of stock-based compensation tied to the second-quarter 2026 acquisitions of Arcellx, Ouro Medicines and Tubulis.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. MANAGEMENT’S DISCUSSION Results of Operations Revenues The following table summarizes our Total revenues and period-over-period changes: Three Months Ended September 30, 2026 Three Months Ended September 30, 2025 (in millions, except percentages) U.S. Europe Rest of World Total U.S. Europe Rest of World Total Change Product sales: HIV Biktarvy $ 3,284 $ 442 $ 333 $ 4,059 $ 2,940 $ 427 $ 320 $ 3,686 10 % Descovy 998 22 26 1,046 652 23 25 701 49 % Genvoya 301 27 12 339 323 34 19 377 (10) % Odefsey 226 52 8 286 206 61 10 277 3 % Symtuza - Revenue share(1) 103 26 3 132 95 26 3 124 7 % Yeztugo 294 — 10 305 39 — — 39 NM Other HIV(2) 55 22 5 82 43 22 8 73 12 % Total HIV 5,261 591 397 6,249…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.